Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

F.D.A. Approves New Treatment for Early Alzheimer’s

The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.

Pam Belluck
Author: Pam Belluck

Written by

Pam Belluck

in

Centers for Medicare and Medicaid Services, Drugs (Pharmaceuticals), Eisai Co Ltd, Food and Drug Administration, Labeling and Labels (Product), Medicare, New England Journal of Medicine, Placebos, United States
←Is The ‘In And Out’ Instagram Trend Worth Trying? Here’s What Experts Say
Love Letter: Stranger Than ‘Sweetie’→

More posts

  • Protesters, leaders push back against DHS over Newark detention facility conditions

  • Goldman and Lander spar hard over Israel

  • Snowflake climbs after Q1 results top expectations, guidance gets a boost

  • Synopsys drops despite better than expected Q2 results, big boost to full-year guidance

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube